Inhibition of efflux transporters by poly ADP-ribose polymerase inhibitors

Forskningsoutput: TidskriftsbidragArtikelVetenskapligPeer review


Abstract Poly ADP-ribose polymerase (PARP) inhibitors have been approved for the treatment of various cancers. They share similar mechanism of action, but have differences in pharmacokinetic characteristics and potential for drug-drug interactions (DDI). This study evaluated the potential ATP-binding cassette transporter-mediated interactions between PARP inhibitors (niraparib, olaparib, and rucaparib) and statins (atorvastatin and rosuvastatin). We studied the inhibitory activity of PARP inhibitors on breast cancer resistance protein (BCRP), multidrug resistance-associated protein 3 (MRP3), and P-glycoprotein (P-gp) using vesicular transport assays and determined the concentrations required for 50% inhibition (IC50). Then, we predicted the increase of statin exposure followed by the administration of PARP inhibitors using a mechanistic static model. Rucaparib was the strongest inhibitor of BCRP-mediated rosuvastatin transport (IC50 13.7 ?M), followed by niraparib (42.6 ?M) and olaparib (216 ?M). PARP inhibitors did not affect MRP3. While niraparib appeared to inhibit P-gp, the inhibition showed large variability. The inhibition of intestinal BCRP by rucaparib, niraparib and olaparib was predicted to elevate rosuvastatin exposure by 52%, 37%, and 24%, respectively. The interactions between PARP inhibitors and rosuvastatin are probably of minor clinical significance alone, but combined with other predisposing factors they may increase the risk of rosuvastatin-associated adverse effects.
TidskriftBasic & Clinical Pharmacology & Toxicology
Sidor (från-till)428-436
Antal sidor9
StatusPublicerad - okt. 2023
MoE-publikationstypA1 Tidskriftsartikel-refererad


  • 3111 Biomedicinska vetenskaper

Citera det här